Welcome to our dedicated page for Lexaria Bioscien news (Ticker: LEXXW), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscien stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) regularly issues news updates that focus on the development and evaluation of its patented DehydraTECH™ oral drug delivery platform. Company press releases highlight progress in human and animal studies, capital raising activities, strategic partnerships, and expansion of its intellectual property portfolio. For followers of LEXXW, this news flow offers insight into how DehydraTECH is being tested and positioned within the pharmaceutical landscape.
A major theme in Lexaria’s recent news is its work with GLP‑1 drugs such as semaglutide, tirzepatide, and liraglutide. The company reports results from multiple human pilot studies and a Phase 1b study in Australia (GLP‑1‑H24‑4), where DehydraTECH‑processed oral formulations are compared against established injectable or oral products. These releases detail safety and tolerability outcomes, reductions in total and gastrointestinal adverse events, and comparative performance on measures like HbA1c, body weight, body composition, and pharmacokinetics.
News items also cover exploratory findings with DehydraTECH‑CBD, including reported blood pressure reductions in a clinical study arm, and pre-clinical work such as a fluorescently tagged semaglutide rodent biodistribution study. Beyond R&D, Lexaria’s announcements describe registered direct offerings on Nasdaq, concurrent warrant placements, and the intended use of proceeds to fund research, working capital, and general corporate purposes.
Additional updates include the extension of a Material Transfer Agreement with a pharmaceutical company to evaluate DehydraTECH, the engagement of a global life science business development advisory firm, and the issuance of new patents in areas such as diabetes, epilepsy, and antiviral treatments. Investors and observers monitoring LEXXW news can use these releases to track Lexaria’s clinical progress, partnering discussions, financing activities, and the evolution of its DehydraTECH-focused strategy over time.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announces significant growth as its DehydraTECHTM technology is now utilized by brands in over 7,000 stores across the US. CEO Chris Bunka highlights the technology's role in boosting market share and sales for clients like Cannadips and New World CBD. The company plans to introduce five new products powered by DehydraTECH in Q4 2021. Lexaria's tech increases bio-absorption significantly and reduces onset time for cannabinoids and other compounds, with ongoing research and licensing efforts enhancing its market position.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) completed dosing in its second human clinical study, HYPER-H21-2, involving 16 participants assessing the effects of DehydraTECH 2.0-enabled CBD on blood pressure. The study, fully funded by company resources, included continuous monitoring and aims to provide insights into potential blood pressure reduction. Preliminary results are expected in September. Additionally, Lexaria received a second patent in Japan, expanding its intellectual property portfolio to 21 patents granted, enhancing its competitive edge in drug delivery technology.
Lexaria Bioscience Corp. announced it received US$3,817,643 from the exercise of warrants linked to its January 2021 public offering. A total of 580,189 shares were issued at an exercise price of US$6.58 per share. The funds will support its ongoing research programs and general corporate needs, with sufficient capital to sustain operations well into 2022. Lexaria's DehydraTECH technology enhances drug absorption and is licensed to various companies, including a major tobacco firm.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the successful achievement of all objectives in its 2021 antiviral drug program. The company tested five compounds from three antiviral drug classes, achieving up to a three-fold increase in oral drug absorption with its DehydraTECH technology. The results showed significant improvements in bioavailability for drugs like Colchicine and Remdesivir. Next steps include larger efficacy evaluations in infected animals and pursuing collaborations for further product development.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced positive results from its study VIRAL-A20-3, demonstrating that its DehydraTECH technology significantly enhances the delivery of colchicine, a drug with potential anti-inflammatory effects useful in treating SARS-CoV-2/COVID-19 symptoms. The study showed a 91% improvement in peak concentration and a 167% increase in total drug delivery compared to control. The findings suggest potential for improved bioavailability of colchicine, which may allow for lower dosing and enhanced therapeutic effects.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has announced promising results from its antiviral drug study, VIRAL-MC21-1, conducted by the National Research Council of Canada. The study confirms that DehydraTECH technology maintains the chemical stability of five tested antiviral drugs, supporting quicker regulatory approvals via the FDA's 505(b)(2) pathway. Key drugs include remdesivir and colchicine, which are associated with COVID-19 treatment. Lexaria plans to seek collaborations with pharmaceutical partners to enhance the application of DehydraTECH in antiviral therapies.
Lexaria Bioscience Corp. has been granted its first patent in Japan, strengthening its intellectual property portfolio, now totaling 20 patents globally. This patent focuses on stable, ready-to-drink beverage compositions containing lipophilic active agents. Lexaria's innovative DehydraTECH platform enhances the bio-absorption of non-psychoactive cannabinoids and NSAIDs, allowing for healthier ingestion methods. The company aims to expand its patent applications globally, targeting a market of nearly 4 billion people.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has announced plans to voluntarily delist its common shares from the Canadian Securities Exchange (CSE) effective July 7, 2021. Starting July 8, 2021, trading will be consolidated on the Nasdaq Capital Markets, where the majority of trading has already occurred since its Nasdaq debut in January 2021. This decision aims to enhance shareholder liquidity and reduce operational costs, allowing the company to focus its resources on applied research and development programs. Lexaria's shares remain qualified investments for Canadian Registered Savings Plans.
Lexaria Bioscience Corp. held its 2021 Annual Meeting on June 28, with 2,735,413 shares represented, comprising 53.6% of its issued capital. Shareholders voted on several proposals, including the election of directors and the appointment of auditors. Key votes included 97.2% approval for Chris Bunka's directorship and 99.2% for auditor appointment. However, an amendment to the Equity Incentive Plan was only 68.3% approved. The company’s DehydraTECH technology continues to enhance drug delivery capabilities across various products, with a robust patent portfolio.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) reports promising results from its study VIRAL-A20-2, demonstrating that its DehydraTECH technology significantly enhances the oral bioavailability of remdesivir and ebastine. Findings indicate that drug levels in the bloodstream can be increased by up to three times compared to non-processed drugs. This improvement may increase the efficacy of these antiviral drugs against SARS-CoV-2. The study was conducted on male rats, with results showing significant improvements in drug delivery metrics.